Every 10-Q that Medifast, Inc. (MED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MED filings page.
Medifast, Inc. reported sharply lower results for the quarter ended June 30, 2026. Revenue fell 27.6% to $76.4 million, driving a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million and $0.22 per diluted share a year earlier. For the first six months of 2026, revenue declined to $152.4 million and the company recorded a $5.2 million net loss. Gross margin compressed to 69.9% in the quarter as lower volumes reduced leverage on fixed costs, while SG&A fell in dollars but rose to 75.6% of revenue, widening the operating loss to 5.7% of sales.
Performance was pressured by a drop in active earning coaches to about 11,700 from 22,800, reflecting weaker client acquisition amid rapid adoption of GLP‑1 weight‑loss medications and a focus on more productive coach structures. Medifast states that active earning coaches are expected to continue declining in 2026, although average quarterly revenue per active coach increased to $6,529, supported by this network realignment.
Strategically, the company is transitioning from its OPTAVIA brand to Trilivy, a broader metabolic‑health platform built around its Metabolic Synchronization® science, new Trilivy Reset fuelings with MetaVantage Technology™, and the Medifast Metabolic Health Institute. Despite current losses, Medifast reports $169.8 million in cash, cash equivalents and investment securities, working capital of $160.5 million, and stockholders’ equity of $196.4 million, supporting its transformation initiatives.
Medifast, Inc. reported a sharp slowdown for the quarter ended March 31, 2026, as revenue fell to $76.0 million from $115.7 million, a 34.3% decline. The company posted a net loss of $2.1 million, or $0.19 per share, compared with a $0.8 million loss, or $0.07 per share, a year earlier.
Results were pressured by a drop in active earning OPTAVIA coaches to 14,000 from 25,400, partly linked to broader adoption of GLP‑1 weight loss medications. Gross margin narrowed to 68.1%, and operating loss widened to $3.3 million. Despite this, Medifast ended the quarter with $168.9 million in cash, cash equivalents, and investments, working capital of $160.4 million, and no debt, while continuing a strategic shift toward holistic metabolic health and new product innovations.
Medifast (MED) reported a weak quarter as demand softened. Revenue was $89.4 million, down 36.2% year over year, and the company posted a net loss of $2.3 million ($0.21 per diluted share) versus a profit a year ago. Nine‑month revenue was $310.7 million, down 35.7%, with a net loss of $0.6 million.
Results reflect a sharp decline in the OPTAVIA coach network and productivity. Active earning coaches fell to 19,500 from 30,000, and average revenue per active coach slipped to $4,585. Gross margin narrowed to 69.5% (down 590 bps), pressured by lower volume leverage and a reserve tied to reformulating the Essential product line. SG&A fell in dollars but remained elevated at 74.1% of revenue.
Liquidity remains solid: cash, cash equivalents and investments were $173.5 million, with working capital of $161.1 million. Operating cash flow was $12.1 million for the nine months. The company exited its LifeMD equity position earlier in the year, contributing to $7.2 million of other income year‑to‑date. Shares outstanding were 10,991,273 as of October 27, 2025.